Thourani Vinod H, Suri Rakesh M, Gunter Rebecca L, Sheng Shubin, O'Brien Sean M, Ailawadi Gorav, Szeto Wilson Y, Dewey Todd M, Guyton Robert A, Bavaria Joseph E, Babaliaros Vasilis, Gammie James S, Svensson Lars, Williams Mathew, Badhwar Vinay, Mack Michael J
Structural Heart and Valve Center, Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia.
Division of Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota.
Ann Thorac Surg. 2015 Jan;99(1):55-61. doi: 10.1016/j.athoracsur.2014.06.050. Epub 2014 Nov 14.
The introduction of transcatheter aortic valve replacement mandates attention to outcomes after surgical aortic valve replacement (SAVR) in low-risk, intermediate-risk, and very high-risk patients.
The study population included 141,905 patients who underwent isolated primary SAVR from 2002 to 2010. Patients were risk-stratified by Society of Thoracic Surgeons (STS) predicted risk of mortality (PROM) <4% (group 1, n = 113,377), 4% to 8% (group 2, n = 19,769), and >8% (group 3, n = 8,759). The majority of patients were considered at low risk (80%), and only 6.2% were categorized as being at high risk. Outcomes were analyzed based on two time periods: 2002 to 2006 (n = 63,754) and 2007 to 2010 (n = 78,151).
The mean age was 65 years in group 1, 77 in group 2, and 77 in group 3 (p < 0.0001). The median STS PROM for the entire population was 1.84: 1.46% in group 1, 5.24% in group 2, and 11.2% in group 3 (p < 0.0001). Compared with PROM, in-hospital mean mortality was lower than expected in all patients (2.5% vs 2.95%) and when analyzed within risk groups was as follows: group 1 (1.4% vs 1.7%), group 2 (5.1% vs 5.5%), and group 3 (11.8% vs 13.7%) (p < 0.0001). In the most recent surgical era, operative mortality was significantly reduced in group 2 (5.4% vs 6.4%, p = 0.002) and group 3 (11.9% vs 14.4%, p = 0.0004) but not in group 1.
Nearly 80% of patients undergoing SAVR have outcomes that are superior to those by the predicted risk models. In the most recent era, early results have further improved in medium-risk and high-risk patients. This large real-world assessment serves as a benchmark for patients with aortic valve stenosis as therapeutic options are further evaluated.
经导管主动脉瓣置换术的引入使得人们必须关注低风险、中风险和极高风险患者接受外科主动脉瓣置换术(SAVR)后的结局。
研究人群包括2002年至2010年接受单纯初次SAVR的141,905例患者。患者根据胸外科医师协会(STS)预测的死亡风险(PROM)进行风险分层:<4%(第1组,n = 113,377)、4%至8%(第2组,n = 19,769)和>8%(第3组,n = 8,759)。大多数患者被认为是低风险(80%),只有6.2%被归类为高风险。结局基于两个时间段进行分析:2002年至2006年(n = 63,754)和2007年至2010年(n = 78,151)。
第1组的平均年龄为65岁,第2组为77岁,第3组为77岁(p < 0.0001)。整个人群的STS PROM中位数为1.84:第1组为1.46%,第2组为5.24%,第3组为11.2%(p < 0.0001)。与PROM相比,所有患者的院内平均死亡率均低于预期(2.5%对2.95%),按风险组分析如下:第1组(1.4%对1.7%)、第2组(5.1%对5.5%)和第3组(11.8%对13.7%)(p < 0.0001)。在最近的手术时代,第2组(5.4%对6.4%,p = 0.002)和第3组(11.9%对14.4%,p = 0.0004)的手术死亡率显著降低,但第1组未降低。
接受SAVR的患者中近80%的结局优于预测风险模型所预测的结局。在最近的时代,中风险和高风险患者的早期结果进一步改善。随着治疗选择的进一步评估,这项大型真实世界评估可为主动脉瓣狭窄患者提供一个基准。